[Evidence-based recommendations on diagnostics and therapy of axial spondyloarthritis : S3 guidelines of the German Society of Rheumatology (DGRh) in cooperation with the Association of the Scientific Medical Societies in Germany (AWMF)].
暂无分享,去创建一个
[1] M. Dougados,et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. , 2015, The New England journal of medicine.
[2] B. Swoboda,et al. [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.6 Invasive therapy]. , 2014, Zeitschrift fur Rheumatologie.
[3] A. Heiligenhaus,et al. [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8 Therapy, 8.1 Treatment concept, 8.2 Therapy targets and strategy]. , 2014, Zeitschrift fur Rheumatologie.
[4] J. Braun,et al. [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 10 Patient information]. , 2014, Zeitschrift fur Rheumatologie.
[5] W. Mau,et al. DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen , 2014, Zeitschrift für Rheumatologie.
[6] B. Swoboda,et al. [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.3 Nonpharmaceutical therapeutic measures]. , 2014, Zeitschrift fur Rheumatologie.
[7] W. Mau,et al. DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen , 2014, Zeitschrift für Rheumatologie.
[8] J. Chenot,et al. DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen , 2014, Zeitschrift für Rheumatologie (Print).
[9] B. Swoboda,et al. DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen , 2014, Zeitschrift für Rheumatologie.
[10] J. Braun,et al. [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 6 Diagnostics]. , 2014, Zeitschrift fur Rheumatologie.
[11] A. Stallmach,et al. DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen , 2014, Zeitschrift für Rheumatologie.
[12] J. Braun,et al. [ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis : evaluation of the 2010 update in the German-speaking area]. , 2013, Zeitschrift fur Rheumatologie.
[13] E. Märker-Hermann,et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. , 2012, Arthritis and rheumatism.
[14] M. Dougados,et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis , 2011, Annals of the rheumatic diseases.
[15] L. Carmona,et al. Prevalence of Vertebral Fractures by Semiautomated Morphometry in Patients with Ankylosing Spondylitis , 2011, The Journal of Rheumatology.
[16] D. M. van der Heijde,et al. Asas/who Icf Core Sets for Ankylosing Spondylitis (as): How to Classify the Impact of as on Functioning and Health Extended Report , 2022 .
[17] E. Märker-Hermann,et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. , 2009, Arthritis and rheumatism.
[18] J. Sieper,et al. The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research , 2008, Annals of the rheumatic diseases.
[19] Andreas Krause,et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial , 2006, Annals of the rheumatic diseases.
[20] J. Braun,et al. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. , 2000, The Journal of rheumatology.
[21] M. Dougados,et al. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. , 1999, The Journal of rheumatology.
[22] M. Dougados,et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. , 1999, The Journal of rheumatology.
[23] A. Calin,et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. , 1994, The Journal of rheumatology.
[24] A. Cats,et al. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.
[25] B. Swoboda,et al. DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen , 2014, Zeitschrift für Rheumatologie.
[26] M. Dougados,et al. Arthritis 2 Spondyloarthritis , 2011 .
[27] A. Boonen,et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. , 2010, Rheumatology.